Skip to main content

Slashdot: Hydroxychloroquine-Promoting COVID Study Retracted After 4 Years

Hydroxychloroquine-Promoting COVID Study Retracted After 4 Years
Published on December 22, 2024 at 12:04AM
Nature magazine reports that "A study that stoked enthusiasm for the now-disproven idea that a cheap malaria drug can treat COVID-19 has been retracted — more than four-and-a-half years after it was published." Researchers had critiqued the controversial paper many times, raising concerns about its data quality and an unclear ethics-approval process. Its eventual withdrawal, on the grounds of concerns over ethical approval and doubts about the conduct of the research, marks the 28th retraction for co-author Didier Raoult, a French microbiologist, formerly at Marseille's Hospital-University Institute Mediterranean Infection (IHU), who shot to global prominence in the pandemic. French investigations found that he and the IHU had violated ethics-approval protocols in numerous studies, and Raoult has now retired. The paper, which has received almost 3,400 citations according to the Web of Science database, is the highest-cited paper on COVID-19 to be retracted, and the second-most-cited retracted paper of any kind.... Because it contributed so much to the HCQ hype, "the most important unintended effect of this study was to partially side-track and slow down the development of anti-COVID-19 drugs at a time when the need for effective treatments was critical", says Ole Søgaard, an infectious-disease physician at Aarhus University Hospital in Denmark, who was not involved with the work or its critiques. "The study was clearly hastily conducted and did not adhere to common scientific and ethical standards...." Three of the study's co-authors had asked to have their names removed from the paper, saying they had doubts about its methods, the retraction notice said. Nature includes this quote from a scientific-integrity consultant in San Francisco, California. "This paper should never have been published — or it should have been retracted immediately after its publication." "The report caught the eye of the celebrity doctor Mehmet Oz," the Atlantic reported in April of 2020 (also noting that co-author Raoult "has made news in recent years as a pan-disciplinary provocateur; he has questioned climate change and Darwinian evolution...") And Nature points out that while the study claimed good results for the 20 patients treated with HCQ, six more HCQ-treated people in the study actually dropped out before it was finished. And of those six people, one died, while three more "were transferred to an intensive-care unit." Thanks to Slashdot reader backslashdot for sharing the news.

Read more of this story at Slashdot.

Comments

Popular posts from this blog

Slashdot: AT&T Says Leaked Data of 70 Million People Is Not From Its Systems

AT&T Says Leaked Data of 70 Million People Is Not From Its Systems Published on March 20, 2024 at 02:15AM An anonymous reader quotes a report from BleepingComputer: AT&T says a massive trove of data impacting 71 million people did not originate from its systems after a hacker leaked it on a cybercrime forum and claimed it was stolen in a 2021 breach of the company. While BleepingComputer has not been able to confirm the legitimacy of all the data in the database, we have confirmed some of the entries are accurate, including those whose data is not publicly accessible for scraping. The data is from an alleged 2021 AT&T data breach that a threat actor known as ShinyHunters attempted to sell on the RaidForums data theft forum for a starting price of $200,000 and incremental offers of $30,000. The hacker stated they would sell it immediately for $1 million. AT&T told BleepingComputer then that the data did not originate from them and that its systems were not breached. ...

Slashdot: US Plans $825 Million Investment For New York Semiconductor R&D Facility

US Plans $825 Million Investment For New York Semiconductor R&D Facility Published on November 02, 2024 at 03:00AM The Biden administration is investing $825 million in a new semiconductor research and development facility in Albany, New York. Reuters reports: The New York facility will be expected to drive innovation in EUV technology, a complex process necessary to make semiconductors, the U.S. Department of Commerce and Natcast, operator of the National Semiconductor Technology Center (NTSC) said. The launch of the facility "represents a key milestone in ensuring the United States remains a global leader in innovation and semiconductor research and development," Commerce Secretary Gina Raimondo said. From the U.S. Department of Commerce press release: EUV Lithography is essential for manufacturing smaller, faster, and more efficient microchips. As the semiconductor industry pushes the limits of Moore's Law, EUV lithography has emerged as a critical technology to ...

Slashdot: AT&T, T-Mobile Prep First RedCap 5G IoT Devices

AT&T, T-Mobile Prep First RedCap 5G IoT Devices Published on October 15, 2024 at 03:20AM The first 5G Internet of Things (IoT) devices are launching soon. According to Fierce Wireless, T-Mobile plans to launch its first RedCap devices by the end of the year, while AT&T's devices are expected sometime in 2025. From the report: All of this should pave the way for higher performance 5G gadgets to make an impact in the world of IoT. RedCap, which stands for reduced capabilities, was introduced as part of the 3GPP's Release 17 5G standard, which was completed -- or frozen in 3GPP terms -- in mid-2022. The specification, which is also called NR-Light, is the first 5G-specific spec for IoT. RedCap promises to offer data transfer speeds of between 30 Mbps to 80 Mbps. The RedCap spec greatly reduces the bandwidth needed for 5G, allowing the signal to run in a 20 MHz channel rather than the 100 MHz channel required for full scale 5G communications. Read more of this story at...